Genta Announces Agreement With FDA on Special Protocol Assessment of Phase 3 Trial of Tesetaxel as Initial Chemotherapy for Women With Metastatic Breast Cancer
June 18, 2012 08:08 ET
|
Genta Incorporated
Proposed trial to compare two oral single agents
Agreement secured on progression-free survival as primary endpoint
BERKELEY HEIGHTS, N.J. , June 18, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated...
Genta Incorporated to Present at 2012 BIO International
June 18, 2012 08:02 ET
|
Genta Incorporated
BERKELEY HEIGHTS, N.J., June 18, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (GNTA) announced that the Company's Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., will provide a...
Genta Initiates Randomized Trial of Tesetaxel as First-Line Therapy for Women With Recurrent Breast Cancer
May 31, 2012 08:05 ET
|
Genta Incorporated
BERKELEY HEIGHTS, N.J., May 31, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (GNTA) announced today that the first patient has been accrued to a new randomized trial of tesetaxel as initial...
Genta Announces Results of Tesetaxel Confirmatory Trial in Patients With Advanced Gastric Cancer
May 24, 2012 08:05 ET
|
Genta Incorporated
-- New Data for Response, Survival, and Safety to be Presented at ASCO
-- Results Support Projections for New Randomized Trial
BERKELEY HEIGHTS, N.J., May 24, 2012 (GLOBE NEWSWIRE) -- Genta...
Tesetaxel Results as Initial Chemotherapy for Women With Recurrent Breast Cancer to be Highlighted at ASCO
May 22, 2012 08:05 ET
|
Genta Incorporated
--Promising results for response and progression-free survival
--Company to proceed with randomized trial
BERKELEY HEIGHTS, N.J., May 22, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (GNTA) today...
Genta Incorporated Reports First Quarter 2012 Financial Results
May 14, 2012 07:58 ET
|
Genta Incorporated
BERKELEY HEIGHTS, N.J., May 14, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA) today reported results for the quarter ended March 31, 2012. For the first quarter of 2012, the Company...
Genta Initiates Randomized Trial of Tesetaxel in Gastric Cancer
May 08, 2012 11:04 ET
|
Genta Incorporated
-- TESEGAST Trial Opens in U.S., EU, and Asia
-- Double-Blind Study Uses "All Oral" Chemotherapy Regimen as 2nd-Line Treatment
BERKELEY HEIGHTS, N.J., May 8, 2012 (GLOBE NEWSWIRE) -- Genta...
Genta Initiates Randomized Trial of Tesetaxel in Gastric Cancer
May 08, 2012 08:05 ET
|
Genta Incorporated
-- TESEGAST Trial Opens in U.S., EU, and Asia
-- Double-Blind Study Uses "All Oral" Chemotherapy Regimen as 2nd-Line Treatment
BERKELEY HEIGHTS, N.J., May 8, 2012 (GLOBE NEWSWIRE) -- Genta...
Genta Appoints Dr. Brian Leyland-Jones and Richard J. Moran to Its Board of Directors
April 24, 2012 08:05 ET
|
Genta Incorporated
BERKELEY HEIGHTS, N.J., April 24, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA) announced today the appointments of Dr. Brian Leyland-Jones and Richard J. Moran, as members of the Company's...
Tesetaxel Clinical Data in Gastric Cancer and Breast Cancer to be Featured at ASCO Annual Meeting
April 04, 2012 08:05 ET
|
Genta Incorporated
BERKELEY HEIGHTS, N.J., April 4, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA) announced today that its lead compound, tesetaxel, will be featured in multiple presentations of new clinical...